Tackling Myasthenia Gravis
Myasthenia gravis (MG) is one of several thousand known diseases affecting fewer than one in 2,000 people. It is a rare disease and has not received the attention it deserves. We were funded by UCB to lead a consensus development programme to build on understanding of what would be required to elevate standards of care for people living with MG in the UK.
This report details our approach and methods as well as the insights and
recommendations about the key areas in which to focus to improve the standards of care for people with MG. These are framed around the four priority areas in the
UK Rare Diseases Framework:
- Helping patients get a diagnosis faster
- Increasing awareness of rare diseases among healthcare professionals
- Better co-ordination of care
- Improving access to specialist care, treatments and drugs.
The report makes recommendations to speed up diagnosis, increase awareness of MG among healthcare professionals, improve co-ordination of care, and improve access to specialist care and drugs. Read the full report to find out more.
